# SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

> **NCT07442565** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 506 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** SYS6010
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07442565
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2027-12-30
- **Final completion:** 2031-05-30
- **Target enrollment:** 506 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07442565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07442565, "SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07442565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*